MSLN and malignant mesothelioma: In terms of studies involving tumor vaccines, evidence suggested that EGCG, as a DC maturation agent, effectively promoted DC maturation and enhanced the anti-cancer effects when administered in combination with mesothelin-specific DNA vaccine, implying this combination application may be a potent immunotherapy strategy against mesothelin-expressing ovarian cancer, pancreatic cancer, and malignant mesothelioma (55).